gefitinib
Not Tagged
[]
 seems like we need to focus on the high risk patients. if we can predict those patients with early pd, we can steer them towards these intensified combination approaches. otherwise we overtreat pts who otherwise would do great on tki alone.
VP, Head of Clinical Development, Foundation Medicine | Thoracic oncology, Boston Medical Center | Husband, father of 4, splitter of wood | Opinions my own